Leadership Center Research, Coordination, Managment and Statistics Program

LCP的目标是在5年内创建一个强大的可持续发展的组织，以提高效率 在AMP RA/SLE网络中进行的临床研究的质量。加拿大皇家骑警将准备好支持 狼疮和类风湿关节炎的研究在更多的地区、国家和国际上进行。该战略旨在 实现这一目标将建立在创建和实施创新协作的基础上 跨LCMP(研究项目管理，业务)核心小组的综合方案 管理、数据协调和管理以及统计研究)和AMP网络 合伙人。LCMP将提供资源和专业知识来支持技术研究人员 研究站点(TRS)、临床研究站点(CRS)和组合站点(CTR)设计、实施、 分析和报告单中心或多中心临床研究。 LCMP将由杰出的临床和运营人员领导，这些人员具有强大的 在科学和临床研究、项目管理和协调、现场管理、数据方面的经验 管理、统计方法、业务发展和财务。所有研究服务都将是 由斯坦福大学及其附属医院、研究中心和 全国各地其他机构的合作者。 LCMP将在未来5年支持进行数十项临床研究，创建一系列 成功地进行了临床研究，清楚地证明了研究的质量表现，严谨 科学研究和聚合临床、实验室和组织数据，这将启发未来 探讨类风湿性关节炎、狼疮以及其他自身免疫性和炎症性疾病。可操作的和 LCMP的临床领导将是帮助NIH实现以下根本目标的宝贵合作伙伴 加速和开拓未来的类风湿和狼疮研究。

The goal of the LCMP is to create, within 5 years, a robust sustainable group that will enhance the efficiency and quality of clinical research performed in the AMP RA/SLE Network. The LCMP will be primed to support lupus and RA research in substantially more sites regionally, nationally, and internationally. The strategy to achieve this goal will be founded upon the creation and implementation of an innovative collaborative integrated program across the core groups of the LCMP (Research Project Management, Operational Management, Data Coordination and Management, and Statistical Research) and the AMP Network partners. The LCMP will provide resources and expertise to support investigators in the Technology Research Sites (TRS), Clinical Research Sites (CRS), and combined sites (CTRS) to design, conduct, analyze, and report single center or multicenter clinical studies. The LCMP will be led by exceptional clinical and operational staff composed of individuals with strong experience in scientific and clinical research, project management and coordination, site management, data management, and statistical methodology, business development and finance. All research services will be provided by the faculty and staff of Stanford University, its affiliated hospitals, research centers and collaborators across the country at other institutions. The LCMP will support the conduct of dozens of clincial studies in the next 5 years creating a portfolio of successfully conducted clinical studies that clearly demonstrate quality of research performance, rigorous scientific investigation, and aggregation of clinical, laboratory, and tissue data that would inspire future exploration in RA, lupus, and additional autoimmune and inflammatory disorders. The operational and clinical leadership of the LCMP will be valuable partners to help NIH achieve the fundamental goal to accelerate and pioneer RA and Lupus research in the future.